Search

Your search keyword '"Hugosson, Jonas"' showing total 1,060 results
Start Over Author "Hugosson, Jonas"
1,060 results on '"Hugosson, Jonas"'

3. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database

Author

Beckmann, Kerri R, Bangma, Chris H, Helleman, Jozien, Bjartell, Anders, Carroll, Peter R, Morgan, Todd, Nieboer, Daan, Santaolalla, Aida, Trock, Bruce J, Valdagni, Riccardo, Roobol, Monique J, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Perry, Antoinette, Hugosson, Jonas, Rubio‐Briones, Jose, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Chung, Byung Ha, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly‐Duffell, Jenna, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Cusick, Thomas, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, and Paich, Kellie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Aging, Prevention, Cancer, Prostate Cancer, Clinical Research, Biopsy, Disease Progression, Humans, Male, Neoplasm Grading, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Watchful Waiting, active surveillance, biopsy schedule, prostate cancer, treatment, upgrading, Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundThe optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatment varied according to intensity of repeat biopsy using data from the GAP3 consortium's global AS database.Materials and methodsIntensity of surveillance biopsy schedules was categorized according to centers' protocols: (a) Prostate Cancer Research International Active Surveillance project (PRIAS) protocols with biopsies at years 1, 4, and 7 (10 centers; 7532 men); (b) biennial biopsies, that is, every other year (8 centers; 4365 men); and (c) annual biopsy schedules (4 centers; 1602 men). Multivariable Cox regression was used to compare outcomes according to biopsy intensity.ResultsOut of the 13,508 eligible participants, 56% were managed according to PRIAS protocols (biopsies at years 1, 4, and 7), 32% via biennial biopsy, and 12% via annual biopsy. After adjusting for baseline characteristics, risk of converting to treatment was greater for those on annual compared with PRIAS biopsy schedules (hazard ratio [HR] = 1.66; 95% confidence interval [CI] = 1.51-1.83; p

Published
2022

5. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Author

Olivier, Jonathan, Li, Weiyu, Nieboer, Daan, Helleman, Jozien, Roobol, Monique, Gnanapragasam, Vincent, Frydenberg, Mark, Sugimoto, Mikio, Carroll, Peter, Morgan, Todd M, Valdagni, Riccardo, Rubio-Briones, Jose, Robert, Grégoire, Stricker, Phillip, Hayen, Andrew, Schoots, Ivo, Haider, Masoom, Moore, Caroline M, Denton, Brian, Villers, Arnauld, Trock, Bruce, Ehdaie, Behfar, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Semjonow, Axel, Rannikko, Antti, Perry, Antoinette, Hugosson, Jonas, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Chung, Byung Ha, van der Kwast, Theo, Hulsen, Tim, van der Linden, Wim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Cusick, Thomas, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, van Bochove, Kees, Kouspou, Michelle, and Paich, Kellie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prevention, Clinical Research, Biomedical Imaging, Clinical Trials and Supportive Activities, Aging, Cancer, Urologic Diseases, Prostate Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Magnetic resonance imaging, Prostate cancer, Active surveillance, Discontinuation, Worldwide, Nomogram, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe inclusion criterion for active surveillance (AS) is low- or intermediate-risk prostate cancer. The predictive value of the presence of a suspicious lesion at magnetic resonance imaging (MRI) at the time of inclusion is insufficiently known.ObjectiveTo evaluate the percentage of patients needing active treatment stratified by the presence or absence of a suspicious lesion at baseline MRI.Design setting and participantsA retrospective analysis of the data from the multicentric AS GAP3 Consortium database was conducted. The inclusion criteria were men with grade group (GG) 1 or GG 2 prostate cancer combined with prostate-specific antigen

Published
2022

6. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume.

Author

Vertosick, Emily A, Zappala, Stephen, Punnen, Sanoj, Hugosson, Jonas, Boorjian, Stephen A, Haese, Alexander, Carroll, Peter, Cooperberg, Matthew, Bjartell, Anders, Lilja, Hans, and Vickers, Andrew J

Subjects
Prostate, Humans, Prostatic Neoplasms, Kallikreins, Prostate-Specific Antigen, Organ Size, Area Under Curve, ROC Curve, Aged, Middle Aged, Male, Neoplasm Grading, Aging, Urologic Diseases, Clinical Research, Cancer, Prostate Cancer, Clinical Sciences, Urology & Nephrology
Abstract

ObjectiveTo assess whether adding prostate volume to the kallikrein panel improves discrimination for ISUP Grade Group 2 or higher (GG2+) disease, as some men may have volume measurements available at the time of blood draw. While prostate volume predicts biopsy outcome, it requires an imaging procedure for measurement. The four kallikrein panel - commercially available as the 4Kscore - predicts risk of GG2+ disease and requires only a blood draw.Materials and methodsA total of 9131 patients with available prostate volume and total PSA ≤25 ng/ml from 5 historical (sextant biopsy, pre-ISUP 2005 grading) and 4 contemporary cohorts (10+ cores, ISUP 2005 grading). Previously published kallikrein panel models were used to predict risk of GG2+. Volume was added to the model in each cohort and change in discrimination was meta-analyzed.ResultsIncreased prostate volume was associated with decreased risk of GG2+ disease after controlling for the kallikrein panel in 7/9 cohorts. However, kallikrein panel discrimination (0.817, 95% CI 0.802, 0.831) was not improved after including volume (AUC difference 0.002, 95% CI -0.003, 0.006). Heterogeneity (P

Published
2021

8. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

Author

Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M, Gnanapragasam, Vincent, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Zhang, Liying, Santa Olalla, Aida, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, La Pointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, and Bruinsma, Sophie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Aging, Prevention, Urologic Diseases, Cancer, Good Health and Well Being, Aged, Asia, Australia, Biopsy, Cause of Death, Clinical Decision-Making, Databases, Factual, Disease Progression, Early Detection of Cancer, Europe, Humans, Kallikreins, Male, Middle Aged, North America, Patient Dropouts, Predictive Value of Tests, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Risk Factors, Time Factors, Watchful Waiting, Prostate cancer, Active surveillance, Discontinuation, Worldwide, Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation.Design, setting, and participantsWe compared data from 10296 men on AS from 21 centres across 12 countries.Outcome measurements and statistical analysisCumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation.Results and limitationsDuring 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for

Published
2019

10. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Ha Chung, Byung, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, Peter van Hooft, Steyerberg, Ewout, Nieboer, Daan, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Cusick, Thomas, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, Paich, Kellie, Helleman, Jozien, Remmers, Sebastiaan, Hyndman, Matthew E., Moore, Caroline M., Shiong Lee, Lui, Elhage, Oussama, Morgan, Todd M., Bangma, Chris H., and Roobol, Monique J.

Published
2022
Full Text
View/download PDF

12. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Ha Chung, Byung, van der Kwast, Theo, Hulsen, Tim, van der Linden, Wim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Nieboer, Daan, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Cusick, Thomas, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, Paich, Kellie, Helleman, Jozien, Li, Weiyu, Morgan, Todd M., Schoots, Ivo, and Moore, Caroline M.

Published
2022
Full Text
View/download PDF

13. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

Author

Pasanen, Niko, primary, Talala, Kirsi, additional, Remmers, Sebastiaan, additional, Tammela, Teuvo L. J., additional, Hugosson, Jonas, additional, Roobol, Monique J., additional, Taari, Kimmo, additional, Arnsrud Godtman, Rebecka, additional, Bangma, Chris, additional, and Auvinen, Anssi, additional

Published
2024
Full Text
View/download PDF

14. Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Ha Chung, Byung, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Nieboer, Daan, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Cusick, Thomas, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, Paich, Kellie, Helleman, Jozien, Shiong Lee, Lui, and Elhage, Oussama

Published
2021
Full Text
View/download PDF

17. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer

Author

Smith, Emma Jane, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Campi, Riccardo, Gacci, Mauro, Bjartell, Anders, Evans-Axelsson, LU Susan, Briganti, Alberto, Gandaglia, Giorgio, Crosti, Daniele, Meoni, Massimiliano, Garzonio, Roberto, Bangma, Chris, Roobol, Monique, Remmers, Sebastiaan, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Van Hemelrijck, Mieke, Beyer, Katharina, Lejeune, Stephane, van Diggelen, Femke, Byrne, Sophie, Fialho, Luz, Cardone, Antonella, Gono, Paulina, De Meulder, Bertrand, Auffray, Charles, Balaur, Irina-Afrodita, Taibi, Nesrine, Power, Shaun, Kermani, Nazanin Zounemat, van Bochove, Kees, Cirillo, Elisa, Moinat, Maxim, Voss, Emma, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Omar, Imran, MacLennan, Sara, MacLennan, Steven, Tripathee, Sheela, Huber, Johannes, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Tandefelt, Delila Gasi, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Asiimwe, Alex, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Chandrawansa, Kumari, Waldeck, Reg, Molnar, Megan, Bruno, Amanda, Herrera, Ronald, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Mohamed, Ateesha, Steinbeißer, Carl, Kedhagae, Siddhanth, Maass, Monika, Torremante, Patrizia, Voss, Marc Dietrich, Devecseri, Zsuzsanna, Abbott, Tom, Kiran, Amit, Dau, Chad, Papineni, Kishore, Wang-silvanto, Jing, Hass, Steve, Snijder, Robert, Doyé, Verena, Wang, Xuewei, Garnham, Andy, Lambrecht, Mark, Wolfinger, Russ, Rogiers, Stijn, Servan, Angela, Casariego, Joaquin, Samir, Mohamed, Pascoe, Katie, Robinson, Paul, Reich, Christian, Ratwani, Shilpa, Longden-Chapman, Elaine, Burke, Danny, Agapow, Paul, Derkits, Sahra, Licour, Muriel, Ang, Michelle, Payne, Sarah, Yong, Alan, Thompson, Lucy, Le Mare, Sophia, Bussmann, Michael, Köhler, Inken, Juckeland, Guido, Kotik, Daniel, MacLennan, Sara J., Mastris, Ken, Hooker, Gary, Greene, Robert, Briers, Erik, Omar, Muhammad Imran, Healey, Jemma, Venderbos, Lionne D.F., Smith, Emma J., Bjorkqvist, Josefine, Roobol, Monique J., and N’Dow, James

Published
2021
Full Text
View/download PDF

20. Which men benefit from prostate cancer screening?:Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

Author

Pasanen, Niko, Talala, Kirsi, Remmers, Sebastiaan, Tammela, Teuvo L. J., Hugosson, Jonas, Roobol, Monique J., Taari, Kimmo, Godtman, Rebecka Arnsrud, Bangma, Chris, Auvinen, Anssi, Pasanen, Niko, Talala, Kirsi, Remmers, Sebastiaan, Tammela, Teuvo L. J., Hugosson, Jonas, Roobol, Monique J., Taari, Kimmo, Godtman, Rebecka Arnsrud, Bangma, Chris, and Auvinen, Anssi

Abstract

ObjectiveTo evaluate whether a subgroup of men can be identified that would benefit more from screening than others.Materials and MethodsThis retrospective cohort study was based on three European Randomised Study of Screening for Prostate Cancer (ERSPC) centres, Finland, the Netherlands and Sweden. We identified 126 827 men aged 55-69 years in the study who were followed for maximum of 16 years after randomisation. The primary outcome was prostate cancer (PCa) mortality. We analysed three age groups 55-59, 60-64 and 65-69 years and PCa cases within four European Association of Urology (EAU) risk groups: low, intermediate, high risk, and advanced disease.ResultsThe hazard ratio (HR) for PCa mortality in the screening arm relative to the control arm for men aged 55-59 years was 0.96 (95% confidence interval [CI] 0.75-1.24) in Finland, 0.70 (95% CI 0.44-1.12) in the Netherlands and 0.42 (95% CI 0.24-0.73) in Sweden. The HR for men aged 60-64 years was 1.03 (95% CI 0.77-1.37) in Finland, 0.76 (95% CI 0.50-1.16) in the Netherlands and 0.97 (95% CI 0.64-1.48) in Sweden. The HR for men aged 65-69 years was 0.80 (95% CI 0.62-1.03) in Finland and 0.57 (95% CI 0.38-0.83) in the Netherlands, and this age group was absent in Sweden. In the EAU risk group analysis, PCa mortality rates were materially lower for men with advanced disease at diagnosis in all three countries: 0.67 (95% CI 0.56-0.82) in Finland, 0.28 (95% CI 0.18-0.44) in the Netherlands, and 0.48 (95% CI 0.30-0.78) in Sweden.ConclusionWe were unable to unequivocally identify the optimal age group for screening, as mortality reduction differed among centres and age groups. Instead, the screening effect appears to depend on screening duration, and the number and frequency of screening rounds. PCa mortality reduction by screening is largely attributable to stage shift.

Published
2024

21. Results after Four Years of Screening for Prostate Cancer with PSA and MRI.

Author

Hugosson, Jonas, Godtman, Rebecka Arnsrud, Wallstrom, Jonas, Axcrona, Ulrika, Bergh, Anders, Egevad, Lars, Geterud, Kjell, Khatami, Ali, Socratous, Andreas, Spyratou, Vasiliki, Svensson, Linda, Stranne, Johan, Månsson, Marianne, and Hellstrom, Mikael

Subjects
*MAGNETIC resonance imaging, *PROSTATE-specific antigen, *PROSTATE cancer, *MEDICAL screening, *EARLY detection of cancer, *CANCER diagnosis
Abstract

BACKGROUND: Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MIU) are needed from studies of follow-up screening. METHODS: In a population-based trial that started in 2015, we invited men who were 50 to years of age to undergo prostate-specific antigen (PSA) screening. Men with a PSA level of 3 ng per milliliter or higher underwent MRI of the prostate. Men were randomly assigned to the systematic biopsy group, in which they underwent systematic biopsy and, if suspicious lesions were found on MRI, targeted biopsy, or the MRI-Patholotargeted biopsy group, in which they underwent MRI-targeted biopsy only. At each visit, men were invited for repeat screening 2,4, or 8 years later, depending on the PSA level. The primary outcome was detection of clinically insignificant (International Society of Urological Pathology [ISUP] grade 1) prostate cancer; detection Inof clinically significant (ISUP grade 22) cancer was a secondary outcome, and detec. Univertion of clinically advanced or high-risk (metastatic or ISUP grade 4 or 5) cancer was also assessed. RESULTS: After a median follow-up of 3.9 years (approximately 26,000 person-years in each group), prostate cancer had been detected in 185 of the 6575 men (2.8°6) in the MRI-targeted biopsy group and 298 of the 6578 men (4.596) in the systematic biopsy group. The relative risk of detecting clinically insignificant cancer in the MRI-targeted biopsy group as compared with the systematic biopsy group was 0.43 (95% confidence interval ICI], 0.32 to 0.57; P<0.001) and was lower at repeat rounds screening than in the first round (relative risk, 0.25 vs. 0.49); the relative risk of diagnosis of clinically significant prostate cancer was 0.84 (95% CI, 0.66 to 1.07). The number of advanced or high-risk cancers detected (by screening or as interval cancer) was 15 in the MRI-targeted biopsy group and 23 in the systematic biopsy group (relative risk, 0.65; 95% CI, 0.34 to 1.24). Five severe adverse events occurred (three in the systematic biopsy group and two in the MIU-targeted biopsy group). CONCLUSIONS: In this trial, omitting biopsy in patients with negative MRI results eliminated more than half of diagnoses of clinically insignificant prostate cancer, and the associated risk of having incurable cancer diagnosed at screening or as interval cancer was very low. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, Jonge, Cees de, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Nieboer, Daan, Zhang, Liying, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, Bruinsma, Sophie, Helleman, Jozien, Kalapara, Arveen A., Verbeek, Jan F.M., Lee, Lui Shiong, Bangma, Chris H., Steyerberg, Ewout W., Harkin, Tim, and Roobol, Monique J.

Published
2020
Full Text
View/download PDF

25. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Rannikko, Antti, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Zhang, Liying, Nieboer, Daan, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, Bruinsma, Sophie, Helleman, Jozien, Drost, Frank-Jan H., Morgan, Todd M., Carroll, Peter R., and Roobol, Monique J.

Published
2019
Full Text
View/download PDF

26. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

Author

Hugosson, Jonas, Roobol, Monique J., Månsson, Marianne, Tammela, Teuvo L.J., Zappa, Marco, Nelen, Vera, Kwiatkowski, Maciej, Lujan, Marcos, Carlsson, Sigrid V., Talala, Kirsi M., Lilja, Hans, Denis, Louis J., Recker, Franz, Paez, Alvaro, Puliti, Donella, Villers, Arnauld, Rebillard, Xavier, Kilpeläinen, Tuomas P., Stenman, Ulf H., Godtman, Rebecka Arnsrud, Stinesen Kollberg, Karin, Moss, Sue M., Kujala, Paula, Taari, Kimmo, Huber, Andreas, van der Kwast, Theodorus, Heijnsdijk, Eveline A., Bangma, Chris, De Koning, Harry J., Schröder, Fritz H., and Auvinen, Anssi

Published
2019
Full Text
View/download PDF

30. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Kakehi, Yoshiyuki, Ha Chung, Byung, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Nieboer, Daan, Zhang, Liying, Santa Olalla, Aida, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, La Pointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, Bruinsma, Sophie, Helleman, Jozien, Ji, Xi, Roobol, Monique J., Bangma, Chris H., Lee, Lui S., Gnanapragasam, Vincent J., and Kattan, Mike W.

Published
2019
Full Text
View/download PDF

39. Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts

Author

Sun, Yinghao, Huang, Yiran, Xie, Liping, Zhou, Liqun, He, Dalin, Ding, Qiang, Wei, Qiang, Shao, Pengfei, Tian, Ye, Sun, Zhongquan, Fu, Qiang, Ma, Lulin, Zheng, Junhua, Ye, Zhangqun, Ye, Dingwei, Xu, Danfeng, Hou, Jianquan, Xu, Kexin, Yuan, Jianlin, Gao, Xin, Liu, Chunxiao, Pan, Tiejun, Gao, Xu, Ren, Shancheng, Xu, Chuanliang, Vickers, Andrew J., Roobol, Monique J., Hugosson, Jonas, Jones, J. Stephen, Kattan, Michael W., Klein, Eric, Hamdy, Freddie, Neal, David, Donovan, Jenny, Parekh, Dipen J., Ankerst, Donna, Bartsch, George, Klocker, Helmut, Horninger, Wolfgang, Benchikh, Amine, Salama, Gilles, Villers, Arnauld, Freedland, Steve J., Moreira, Daniel M., Schröder, Fritz H., Lilja, Hans, Cronin, Angel M., Chen, Rui, and Sjoberg, Daniel D.

Published
2017
Full Text
View/download PDF

40. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Author

Smith, Emma, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Abbott, Tom, Mastris, Ken, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Fossati, Nicola, Pang, Karl, Campi, Riccardo, Greco, Isabella, Gacci, Mauro, Serni, Sergio, Bjartell, Anders, Lonnerbro, Ragnar, Briganti, Alberto, Crosti, Daniele, Garzonio, Roberto, Gandaglia, Giorgio, Faticoni, Martina, Grant office, Bangma, Chris, Jongerden, Maria, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Lejeune, Stephane, Colette, Laurence, Caputova, Simona, Poli, Delielena, Byrne, Sophie, Fialho, Luz, Rowland, Ashley, Tapela, Neo, Di Flora, Nicola, Apostolidis, Kathi, Lemair, Valerie, De Meulder, Bertrand, Auffray, Charles, Taibi, Nesrine, Hijazy, Ayman, Saporta, Albert, Sun, Kai, Power, Shaun, Zounemat Kermani, Nazanin, van Bochove, Kees, Tafreshiha, Azadeh, Bernini, Chiara, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Tripathee, Sheela, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Gasi Tandefelt, Delila, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Tames Grijalva, Monica, Evans-Axelsson, Susan, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Waldeck, Reg, Bruno, Amanda, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Steinbeisser, Carl, Maass, Monika, Torremante, Patrizia, Dochy, Emmanuelle, Pisa, Federica, Voss, Marc Dietrich, Papineni, Kishore, Wang-silvanto, Jing, Snijder, Robert, Wang, Xuewei, Lambrecht, Mark, Wolfinger, Russ, Eid, Sherinne, Palanisamy, Soundarya, Haque, Samiul, Antoni, Laurent, Servan, Angela, Pascoe, Katie, Robinson, Paul, Lencart, Joana, Jaton, Bertrand, Turunen, Heidi, Kilkku, Olavi, Pohjanjousi, Pasi, Voima, Olli, Nevalaita, Liina, Punakivi, Keijo, Seager, Sarah, Ratwani, Shilpa, Grzeslak, Katarzyna, Brash, James, Longden-Chapman, Elaine, Burke, Danny, Licour, Muriel, Payne, Sarah, Yong, Alan, Lujan, Flavia, Le Mare, Sophia, Hendrich, Jan, Bussmann, Michael, Juckeland, Kotik, Reich, Christian, Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, and Van Hemelrijck, Mieke

Published
2024
Full Text
View/download PDF

50. Corrigendum to “Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial” [Eur Urol (2022)]

Author

Carlsson, Sigrid V., primary, Godtman, Rebecka Arnsrud, additional, Pihl, Carl-Gustav, additional, Vickers, Andrew, additional, Lilja, Hans, additional, Hugosson, Jonas, additional, and Månsson, Marianne, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results